Projects

Search from 1167 projects:

Reset RSS

Time frame

Year

Year To

Project type

Project status

Unit

Recruitment

Labels

5 Project(s)

Oct 7, 2024

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Oct 7, 2024

Clinical Studies - Oct 7, 2024 - Oct 9, 2028

Ongoing

Project leader: Schittenhelm Marcus
Members: Dei Cas Alissa

Oct 13, 2021

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by oneyear mainte-nance in patients with newly diagnosed Acute Myeloid Leu-kemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Oct 13, 2021

Das Ziel dieser Studie ist es, die Therapie einer akuten myeloischen Leukämie (AML) oder eines myelodysplastischen Syndroms mit erhöhter Anzahl an Leukämiezellen (MDS-EB2) zu verbessern. Wir möchten nun die Wirksamkeit und Sicherheit von Gilteritinib...

Clinical Studies - Oct 13, 2021 - Jul 26, 2028

Ongoing

Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine

Jul 30, 2021

CAR T- Cell EBMT Registry data processing framework

Jul 30, 2021

Clinical Studies - Jul 30, 2021 - Dec 31, 2026

Ongoing

Project leader: Fehr Martin
Members: Breuss Kim, Müller Fiona

Dec 18, 2019

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Dec 18, 2019

IDH1 or IDH2 mutations are each found in about 10% of AML – and specific inhibitors are approved or in development in this indication. The primary objective of this study is to compare event-free survival (EFS) between ivosidenib/enasidenib and pl...

Clinical Studies - Dec 18, 2019 - Jan 31, 2027

Ongoing

Project leader: Schittenhelm Marcus
Members: Kehl Jeanine, Quinter Janine

May 17, 2018

Multicentre Oberservational Study of MDS Patients in Switzerland- Swiss MDS Registry

May 17, 2018

Die Myelodysplastischen Syndrome (MDS) umfassen eine heterogene Gruppe hämatologischer Stammzellerkran-kungen, welche durch Reifungsstörungen des Knochen-markes (Dysplasien) mit Verminderung der Blutzellen (Zy-topenien) charakterisiert sind. Das Spek...

Clinical Studies - May 17, 2018 - Aug 14, 2030

Ongoing

Project leader: Silzle Tobias
Members: Steiner Marianne